| Literature DB >> 31076811 |
Johannes Kohlmann1, Jan Christoph Simon2, Manfred Kunz2, Regina Treudler2.
Abstract
The role of interleukin-17 (IL-17) in pemphigoid diseases is not fully understood. Both pemphigus vulgaris (PV) as well as pemphigus foliaceus (PF) show intralesional IL-17 positive cells. A patient with initially assumed coexisting PF and psoriasis pustulosa (PP) was treated with the anti-IL-17 antibody secukinumab. The clinical skin picture markedly improved and the level of anti-desmoglein-1 antibodies clearly decreased; however, with the prolongation of injection intervals of secukinumab, autoantibody levels started to rise again. A dose-dependent effect of secukinumab on autoantibody production in PF is suspected. Retrospectively, a neutrophilic PF can be discussed in the present case, where almost complete healing was achieved under IL-17 blockade treatment.Entities:
Keywords: Antibodies, monoclonal; Autoantibodies; Desmoglein 1; Psoriasis; Secukinumab
Mesh：
Substances：
Year: 2019 PMID： 31076811 DOI： 10.1007/s00105-019-4414-8
Source DB: PubMed Journal: Hautarzt ISSN： 0017-8470 Impact factor: 0.751